To point out to the significance of this finding are data indicating that: i) the increased expression of CD40L on peripheral blood CD4+ T cells has been approved as a marker of disease activity in RA65 and ii) the CD40L/CD40 pathway has recently been recognized as a potential target for innovative therapy in several autoimmune diseases, including RA42. This evidence concerns the gene CD40 and autoimmune disease.